ONDAMED and Smoking Cessation A Statistical Analysis

Similar documents
Happy Ending: a randomized controlled trial of a digital multi-media smoking cessation intervention

Non-inferiority studies: non-sense or sense?

Online 12 - Sections 9.1 and 9.2-Doug Ensley

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Helping People to Stop Smoking

Types of Studies. Systematic Reviews and Meta-Analyses

Smoking Cessation in People with Severe Mental Illness. Lisa Dixon, M.D., MPH and Melanie Bennett, Ph.D. University of Maryland School of Medicine

How To Stop Smoking. Tamra Casper

Menthol cigarettes and smoking cessation behavior Authors: Allison C. Hoffman, FDA CTP; Donna Miceli, DLM Writing Services

400,000 people in the United States die every year due to smoking-related illnesses.

Smoking Cessation: Treatment Options for Nicotine Addiction

Pharmacotherapy for Nicotine Dependence

Nicotine Testing Common Questions

c. Construct a boxplot for the data. Write a one sentence interpretation of your graph.

T obacco use is rising among young adults (aged 18 24

Biochemistry and Medical Treatment. of Tobacco Addiction Smoking Consultation Service

Helping Smokers Quit

Recommended Dosage: For smokers who smoke over 25 cigarettes a day: HOW TO USE TBX-FREE TO HELP QUIT SMOKING: THE KEYS TO SUCCESS:

2009 Mississippi Youth Tobacco Survey. Office of Health Data and Research Office of Tobacco Control Mississippi State Department of Health

Tobacco Addiction. Presented by: Dawn M. Dunn, M.P.H. & Dotsie Anfenson

Tobacco Use Among Students Attending Historically Black Colleges and Universities: Prevalence, Patterns and Norms

Empowering smokers with a web-assisted tobacco intervention to use prescription smoking cessation medications: a feasibility trial

Patient information. How to Stop Smoking Before your Operation PIF 734 V5

Cancer Clinical Trials: The Basics

Policy overview 1. Purpose/Principles 2. Scope 3. Definitions 4. Policy 5. Procedures

APA Sample Paper. Running head: SMOKING CESSATION STRATEGIES 1. Smoking Cessation Strategies. Student Name. School Name

Smoking Cessation Program

ESCMID Online Lecture Library. by author

Grant ID Page 4 Medical University of South Carolina Implementation of TelASK Quit Connection IVR System in Charleston Area Hospitals

Math 201: Statistics November 30, 2006

Chapter 7 Review. Confidence Intervals. MULTIPLE CHOICE. Choose the one alternative that best completes the statement or answers the question.

STANDARD TREATMENT PROGRAMME. A guide to providing behavioural support for smoking cessation

National Standard for Tobacco Cessation Support Programme

Comparing Two Groups. Standard Error of ȳ 1 ȳ 2. Setting. Two Independent Samples

Delivery of Tobacco Dependence Treatment for Tobacco Users with Mental Illness and Substance Use Disorders (MISUD)

Clinical Trials Network

The Promise and Challenge of Adaptive Design in Oncology Trials

Chi-square test Fisher s Exact test

Chapter 2 Probability Topics SPSS T tests

Smoking Cessation Program

Smoking cessation guidelines for health professionals: an update

Web appendix: Supplementary material. Appendix 1 (on-line): Medline search strategy

The Pharmacy Technician s Role In Smoking Cessation Programs. Presented by Thomas Flench, R.Ph., MBA

Self-help interventions for smoking cessation (Review)

Health Science / Anatomy Exam 1 Study Guide

What is a P-value? Ronald A. Thisted, PhD Departments of Statistics and Health Studies The University of Chicago

Internet and Mobile Phone Studies (E-epidemiology)

RR 0.88 (95% CI: ) P=0.051 (superiority) 3.75

Survey of Wisconsin Renters: Smoking Rules, Attitudes & Preferences

Preventive Medicine and the Need for Routine Hearing Screening in Adults

INTRODUCTION. Tobacco Prevention & Cessation Program Substance Abuse and Tobacco Cessation Report - March 2011

DESCRIPTIVE STATISTICS - CHAPTERS 1 & 2 1

3.2 Conditional Probability and Independent Events

Use of electronic cigarettes (vapourisers) among adults in Great Britain

FOREVER FREE STOP SMOKING FOR GOOD B O O K L E T. StopSmoking. ForGood. The Road Ahead

Questions and Answers About Smoking Cessation

BOOKLET 8. A Guide To Remaining Smoke Free FOR PERSONAL USE ONLY. DO NOT DUPLICATE. Life Without Cigarettes

p ˆ (sample mean and sample

Venous Thromboembolism: Long Term Anticoagulation. Dan Johnson, Pharm.D.

The CCB Science 2 Service Distance Learning Program

YOU CAN QUIT WE CAN HELP

Utilization of Services in a Randomized Trial Testing Phone- and Web-based Behavioral Interventions for Smoking Cessation

Breadth of indications matters One drug for multiple indications

Loss Control TIPS Technical Information Paper Series

Power Analysis: Intermediate Course in the UCLA Statistical Consulting Series on Power

HYPOTHESIS TESTING (ONE SAMPLE) - CHAPTER 7 1. used confidence intervals to answer questions such as...

What You Need to Know When Quitting Smoking

Analysis and Interpretation of Clinical Trials. How to conclude?

Regulatory decision-making for the assessment of ECG effects of new drugs: Exposure-response analyis

MILITARY TOBACCO USE: OVERVIEW OF USE AND OPPORTUNITIES TO PROVIDE TOBACCO CESSATION TO STUDENT VETERANS. Session Two

Comparison/Control Groups. Mary Foulkes, PhD Johns Hopkins University

A Pregnant Woman s Self-Help Guide to Quit Smoking

REPORT TO CONGRESS REQUIRED BY SECTION 918 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT AS AMENDED BY PUBLIC LAW

Simple Random Sampling

Cigarettes and Other Tobacco Products

Varenicline - Guidance for health professionals on a new prescription-only stop smoking medication

HYPOTHESIS TESTING (ONE SAMPLE) - CHAPTER 7 1. used confidence intervals to answer questions such as...

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015

Questions about stopping tobacco use

Stop Smoking. Key #2. It s Not Too Late to Benefit from Quitting! Health Benefits to Quitting. Other Reasons to Quit

Hypothesis testing - Steps

Name of Program: Healthy Bean. Company/Organization: L.L.Bean, Inc. Address: 15 Casco St. City/State/Zip: Freeport, Maine 04033

Clinical Trial Designs for Firstline Hormonal Treatment of Metastatic Breast Cancer

Final Exam Practice Problem Answers

Cigarette Smoking and Naltrexone - A New Series

Smoking and the risk of stroke

MOUTH CANCER. How to spot the signs and symptoms and reduce your risk. cruk.org


NHS Whittington Health/ Smokefree Islington <Enter date>

Advanced Statistical Analysis of Mortality. Rhodes, Thomas E. and Freitas, Stephen A. MIB, Inc. 160 University Avenue. Westwood, MA 02090

A list of FDA-approved testosterone products can be found by searching for testosterone at

Cancer Clinical Trials & You:

C. The null hypothesis is not rejected when the alternative hypothesis is true. A. population parameters.

Review. March 21, S7.1 2_3 Estimating a Population Proportion. Chapter 7 Estimates and Sample Sizes. Test 2 (Chapters 4, 5, & 6) Results

Lesson Outline Outline

Clinical Study Synopsis

Clinical Study Synopsis for Public Disclosure

Smoking Cessation and Mental Health: A briefing for front-line staff

Transcription:

ONDAMED and Smoking Cessation A Statistical Analysis Thomas R. Sexton, Ph.D. Stony Brook University Revised January 25, 2009 This report analyzes data from two groups of subjects treated with ONDAMED for smoking cessation. Group 1 includes n=103 subjects while Group 4 includes n=74 subjects. Data from Groups 2 and 3 were not suitable for analysis because the period is either unreported (Group 2) or vague (Group 3). The statistical analysis consists of the percentage of subjects within each group who were nonsmokers at each time at which data are reported, along with 95% confidence intervals for the percentages. Each group is analyzed separately and in combination. In addition, this report compares the results from the ONDAMED trials with those from Shiffman, et al. 1, who tested the efficacy of nicotine gum in facilitating smoking cessation through gradual reduction. The statistical analysis consists of hypothesis tests to determine if the success rate one month and six months after 24 hour abstinence while using nicotine gum differs from the success rate one month and six months after treatment with ONDAMED. Results Success Rates in ONDAMED Trials Table 1 and Figure 1 show the results for Group 1, Table 2 and Figure 2 show the results for Group 4, and Table 3 and Figure 3 show the results for the combined groups. 1

Table 1: Results for Group 1 (103 subjects). ME = Margin of Error for the 95% confidence interval. Time Nonsmokers Percentage ME Lower CI Upper CI 0 days 103 100.0% 0.0% 100.0% 100.0% 14 days 86 83.5% 7.2% 76.3% 90.7% 1 month 77 74.8% 8.4% 66.4% 83.1% 3 months 65 63.1% 9.3% 53.8% 72.4% 6 months 52 50.5% 9.7% 40.8% 60.1% 1 year 40 38.8% 9.4% 29.4% 48.2% 2

Table 2: Results for Group 4 (74 subjects). ME = Margin of Error for the 95% confidence interval. Time Nonsmokers Percentage ME Lower CI Upper CI 0 days 74 100.0% 0.0% 100.0% 100.0% 14 days 1 month 3 months 6 months 54 73.0% 10.1% 62.9% 83.1% 1 year 3

Table 3: Results for Groups 1 and 4 combined (177 subjects). ME = Margin of Error for the 95% confidence interval. Time Nonsmokers Percentage ME Lower CI Upper CI 0 days 177 100.0% 0.0% 100.0% 100.0% 14 days 1 month 3 months 6 months 106 59.9% 7.2% 52.7% 67.1% 1 year 4

Comparison of ONDAMED with Nicotine Gum Shiffman, et al. 1 enrolled 3297 smokers who then self selected either 2 mg or 4 mg nicotine gum after reviewing the label instructions, which told subjects who smoked at least 25 cigarettes per day to select the 4 mg dose and those who smoked less to select the 2 mg dose. Self selection complied with these instructions in 88.3% of all cases, with 1636 subjects in the 2 mg group and 1661 in the 4 mg group. Within each dosage group, subjects were randomly assigned to either treatment with the selected dose or a placebo gum. All subjects were instructed to gradually replace cigarettes with gum for one additional hour per day until they achieved abstinence from smoking for 24 hours. They then continued to use the gum according to FDA approved labeling for 12 weeks and then as needed to stay smokefree for an additional 12 weeks. The primary study endpoint was achievement of 28 day continuous abstinence. Reduction in smoking, achievement of initial 24 hour abstinence, and abstinence at six months were also reported. Table 4 shows the progression of subjects through the trial. Table 4: Progression of subjects through the trials reported in Shiffman, et al. 1 Enrolled n = 3297 Self Selected Group 2 mg; n = 1636 4 mg; n = 1661 Randomly Allocated 817 placebo 819 active 831 placebo 830 active 24 Hour Abstinence 195 252 109 184 28 Day Abstinence 45 86 21 88 6 Month Abstinence 40 75 18 78 The success rates using nicotine gum may be computed in two ways. In the first method, we use the number of subjects randomly assigned to active treatment as the denominator. In the second method, we use only those subjects in the active treatment group who achieved 24 hour abstinence as the denominator. Table 5 shows the success rates for ONDAMED along with the success rates for the 2 mg dose of nicotine gum, while Table 6 shows the results for the 4 mg dose of nicotine gum. Table 5: Success rates for ONDAMED and 2 mg nicotine gum at one month (28 days) and six months. Time Ondamed 2 mg Nicotine Gum All Subjects 24 Hour Abstinence 1 Month (28 Days) 77/103 = 74.8% 86/819 = 10.5% 86/252 = 34.1% 6 Months 106/177 = 59.9% 75/819 = 9.2% 75/252 = 29.8% 5

Table 6: Success rates for ONDAMED and 4 mg nicotine gum at one month (28 days) and six months. Time ONDAMED 4 mg Nicotine Gum All Subjects 24 Hour Abstinence 1 Month (28 Days) 77/103 = 74.8% 88/830 = 10.6% 88/184 = 47.8% 6 Months 106/177 = 59.9% 78/830 = 9.4% 78/184 = 42.4% There are eight comparisons of ONDAMED versus nicotine gum: two dosages at two times and using two denominators (all subjects and only those who achieved 24 hour abstinence). Each comparison involves a two tailed, two sample hypothesis test of proportions, which were performed using the normal distribution test with correction for continuity. In all comparisons except one, the P value for the test is less than 0.00005. In the comparison of ONDAMED versus 4 mg nicotine gum at 6 months and using only those subjects who achieved 24 hour abstinence, the P value is 0.0013. Thus, we conclude with near certainty that the subjects who were treated with ONDAMED experienced a higher success rate at both one month and six months than did those who used nicotine gum at either dose. There are at least two caveats that apply to this conclusion. 1. The subjects in the Shiffman, et al., study had all expressed the desire to quit smoking gradually rather than at once. Thus, they may have been less committed to quitting than some of the patients in the ONDAMED study. 2. The subjects in the Shiffman, et al., study were tested twice for carbon monoxide in their breath and, in some cases, for serum cyothianate to protect against unreliable self reporting of smoking behavior. Reference 1. Shiffman S, Ferguson SG, Strahs KR. Quitting by gradual smoking reduction using nicotine gum: a randomized controlled trial. Am J Prev Med 2009;36(2):96 104. 6